Grace Therapeutics (GRCE) Receivables - Net (2017 - 2024)
Grace Therapeutics (GRCE) posted Receivables - Net of $398000.0 for Q2 2024, down 44.88% sequentially from $722000.0 in Q1 2024, and down 52.45% YoY from $837000.0 in Q3 2023.
Grace Therapeutics (GRCE) Receivables - Net (2017 - 2024) Analysis & Trends
Grace Therapeutics has reported Receivables - Net for 8 years, with the latest figure at $398000.0 in Q2 2024.
- Quarterly Receivables - Net fell 52.45% year-over-year to $398000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $398000.0 (down 52.45% YoY) and the FY2024 annual result came in at $722000.0, down 9.98% from the prior year.
- Receivables - Net retreated to $398000.0 in Q2 2024 per GRCE's latest filing, from $722000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $964000.0 in Q2 2022 and troughed at $238000.0 in Q4 2021.
- A 5-year average of $667666.7 and a median of $673500.0 in 2020 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2021 and 2022: Receivables - Net slumped 61.55% in 2021, then surged 226.89% in 2022.
- Over 5 years, Receivables - Net stood at $619000.0 in 2020, then plunged by 61.55% to $238000.0 in 2021, then soared by 226.89% to $778000.0 in 2022, then gained by 23.26% to $959000.0 in 2023, then tumbled by 58.5% to $398000.0 in 2024.
- According to Business Quant data, Receivables - Net over the past three periods registered $398000.0, $722000.0, and $959000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 398,000.00 |
| Jun 30, 2024 | 398,000.00 |
| Mar 31, 2024 | 722,000.00 |
| Mar 31, 2024 | 722,000.00 |
| Dec 31, 2023 | 959,000.00 |
| Dec 31, 2023 | 959,000.00 |
| Sep 30, 2023 | 837,000.00 |
| Sep 30, 2023 | 837,000.00 |
| Jun 30, 2023 | 837,000.00 |
| Jun 30, 2023 | 837,000.00 |
| Mar 31, 2023 | 802,000.00 |
| Mar 31, 2023 | 802,000.00 |
| Dec 31, 2022 | 778,000.00 |
| Dec 31, 2022 | 778,000.00 |
| Sep 30, 2022 | 859,000.00 |
| Sep 30, 2022 | 859,000.00 |
| Jun 30, 2022 | 964,000.00 |
| Jun 30, 2022 | 964,000.00 |
| Mar 31, 2022 | 548,000.00 |
| Mar 31, 2022 | 548,000.00 |